AI-Powered Drug Discovery Identifies New Target for PARP-Resistant Cancers

Researchers at MD Anderson used machine learning to identify GRB2i as a target for overcoming PARP inhibitor resistance in cancer treatment.

Researchers at UT MD Anderson Cancer Center used artificial intelligence to identify GRB2i as a promising therapeutic target for cancers that have developed resistance to PARP inhibitors, as @UTMDAnderson reported. PARP inhibitor resistance is a significant clinical challenge, particularly in ovarian and breast cancers, and identifying new targets through computational methods could accelerate the development of combination therapies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia curae.

Unlock the full briefing

Get every story in today's briefing, the full archive, and the daily AI intelligence brief.

All stories today

Full archive

Daily brief